# OnCo record dabrafenib-trametinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/dabrafenib-trametinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "dabrafenib-trametinib" ;
  schema:name "Dabrafenib + trametinib"@en ;
  schema:description "Dabrafenib plus trametinib is the BRAF-plus-MEK pill combination, approved for BRAF V600E lung cancer and, since 2022, for any solid tumour with that mutation."@en ;
  schema:url <https://onco.cc/drugs/dabrafenib-trametinib/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Dabrafenib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q3011604> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Dabrafenib>, <https://www.nice.org.uk/guidance/ta898> ;
  onco:status "approved" ;
  onco:modality "Small-molecule kinase inhibitors (BRAF + MEK)" ;
  schema:alternateName "Tafinlar + Mekinist" ;
  onco:approval "US 2014: BRAF V600E/K unresectable or metastatic melanoma, combination (accelerated; each drug alone approved 2013)", "US 2017: BRAF V600E metastatic NSCLC", "US 2022: BRAF V600E solid tumours, tumour-agnostic (age ≥6)", "England (NICE) 2023: BRAF V600 mutation-positive advanced non-small-cell lung cancer, first line only" ;
  onco:related <https://onco.cc/pairings/braf-plus-mek/>, <https://onco.cc/biomarkers/braf-v600e/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/thyroid/>, <https://onco.cc/cancers/paediatric-low-grade-glioma/>, <https://onco.cc/cancers/paediatric-high-grade-glioma/>, <https://onco.cc/cancers/secondary-brain-tumours/>, <https://onco.cc/cancers/braf-v600e-nsclc/>, <https://onco.cc/cancers/braf-v600-melanoma/>, <https://onco.cc/cancers/stage-iii-melanoma/>, <https://onco.cc/cancers/advanced-melanoma/>, <https://onco.cc/cancers/lung-cancer/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/braf/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:terms <https://onco.cc/terms/tumour-agnostic/> ;
  onco:trials <https://onco.cc/trials/brf113928/>, <https://onco.cc/trials/pharos/> .